Actively Recruiting
Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma
Led by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Updated on 2026-04-03
20
Participants Needed
1
Research Sites
283 weeks
Total Duration
On this page
Sponsors
S
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lead Sponsor
R
Robert L. Sloan Fund for Cancer Research
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.
CONDITIONS
Official Title
Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Biopsy confirmed diagnosis of renal cell carcinoma
- No clinical or imaging evidence of cancer spread (metastatic disease)
- Not eligible for surgery or local ablative treatments
- Able to undergo MRI or contrast-enhanced CT scan
You will not qualify if you...
- Previous radiation therapy with overlapping treatment areas
- Known metastatic kidney cancer
- Pregnant women or those planning pregnancy during treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sibley Memorial Hospital
Washington D.C., District of Columbia, United States, 20016
Actively Recruiting
Research Team
S
Sherif Shaaban
CONTACT
R
Ryan Manuel
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here